Reuters logo
BRIEF-Supernus receives final FDA approval for trokendi XR
April 5, 2017 / 11:04 PM / in 7 months

BRIEF-Supernus receives final FDA approval for trokendi XR

April 5 (Reuters) - Supernus Pharmaceuticals Inc:

* Supernus receives final FDA approval for trokendi XR for migraine prophylaxis in adults and adolescents

* Supernus Pharmaceuticals Inc - FDA granted final approval to co’s supplemental new drug applications requesting label expansion for trokendi XR Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below